These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 27898521)

  • 21. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
    Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
    Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
    [No Abstract]   [Full Text] [Related]  

  • 25. Precursors to pelvic serous carcinoma and their clinical implications.
    Folkins AK; Jarboe EA; Roh MH; Crum CP
    Gynecol Oncol; 2009 Jun; 113(3):391-6. PubMed ID: 19237187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
    Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
    Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
    Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
    Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J; Shi JL; Shen DH; Chen YX; Song QJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
    Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.
    Otsuka I
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer.
    Galhenage P; Zhou Y; Perry E; Loc B; Fietz K; Iyer S; Reinhardt F; Da Silva T; Botchkarev V; Chen J; Crum CP; Weinberg RA; Pathania S
    Cell Rep; 2023 Oct; 42(10):113144. PubMed ID: 37729060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
    Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
    Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
    Ngoi NYL; Tan DSP
    ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    Morgan RD; Clamp AR; Evans DGR; Edmondson RJ; Jayson GC
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):647-658. PubMed ID: 29464354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.